Cytokinetics Inc (NASDAQ: CYTK) is -34.27% lower on its value in year-to-date trading and has touched a low of $30.37 and a high of $110.25 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CYTK stock was last observed hovering at around $53.15 in the last trading session, with the day’s gains setting it 1.73%.
Currently trading at $54.88, the stock is 1.32% and -0.20% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.15 million and changing 3.25% at the moment leaves the stock -14.44% off its SMA200. CYTK registered 52.66% gain for a year compared to 6-month loss of -23.31%. The firm has a 50-day simple moving average (SMA 50) of $54.992 and a 200-day simple moving average (SMA200) of $64.1393.
The stock witnessed a 1.52% gain in the last 1 month and extending the period to 3 months gives it a -4.37%, and is -3.18% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.39% over the week and 3.98% over the month.
Cytokinetics Inc (CYTK) has around 423 employees, a market worth around $6.46B and $3.13M in sales. Profit margin for the company is -17398.82%. Distance from 52-week low is 80.70% and -50.22% from its 52-week high. The company has generated returns on investments over the last 12 months (-62.77%).
with sales reaching $1.19M over the same period.The EPS is expected to grow by 6.02% this year, but quarterly earnings will post -2.50% year-over-year. Quarterly sales are estimated to grow 214.80% in year-over-year returns.
Cytokinetics Inc (CYTK) Top Institutional Holders
471.0 institutions hold shares in Cytokinetics Inc (CYTK), with institutional investors hold 118.60% of the company’s shares. The shares outstanding are 117.66M, and float is at 113.74M with Short Float at 15.23%. Institutions hold 118.00% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 14.67 million shares valued at $794.97 million. The investor’s holdings represent 14.3958% of the CYTK Shares outstanding. As of 2024-06-30, the second largest holder is FMR LLC with 11.52 million shares valued at $624.32 million to account for 11.3056 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 11.44 million shares representing 11.2218% and valued at over $619.69 million, while T. ROWE PRICE INVESTMENT MANAGEMENT, INC. holds 7.985 of the shares totaling 8.14 million with a market value of $440.95 million.
Cytokinetics Inc (CYTK) Insider Activity
The most recent transaction is an insider sale by Blum Robert I, the company’s President & CEO. SEC filings show that Blum Robert I sold 5,000 shares of the company’s common stock on Oct 09 ’24 at a price of $55.61 per share for a total of $0.28 million. Following the sale, the insider now owns 0.4 million shares.
Still, SEC filings show that on Oct 01 ’24, Malik Fady Ibraham (EVP Research & Development) disposed off 7,300 shares at an average price of $52.10 for $0.38 million. The insider now directly holds 118,920 shares of Cytokinetics Inc (CYTK).
